已收盘 12-19 16:00:00 美东时间
+0.830
+3.14%
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
12-18 10:54
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
12-15 15:30
Wells Fargo analyst Eva Fortea Verdejo upgrades Zymeworks (NASDAQ:ZYME) from Equal-Weight to Overweight and raises the price target from $25 to $33.
12-13 00:29
Citi analyst Yigal Nochomovitz maintained a Buy rating on Zymeworks on December...
12-08 07:55
今日重点评级关注:Guggenheim:维持Cybin Inc. Common Shares"买入"评级,目标价从39美元升至48美元;HC Wainwright & Co.:维持Capricor Therapeutics"买入"评级,目标价从24美元升至60美元
12-04 09:38
Citizens analyst Reni J. Benjamin initiates coverage on Zymeworks (NASDAQ:ZYME) with a Market Outperform rating and announces Price Target of $32.
12-03 23:58
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总。以下是由 The Fly 整理的今日投资者需关注的研究评级信息。 五家评级上调的公司 Arete...
12-03 22:58
Zymeworks Inc. announced its participation in upcoming conferences. At the ASCO Gastrointestinal Cancers Symposium (January 8-10, 2026, San Francisco, CA), Zymeworks will present ZW251, a GPC3-targeting ADC for hepatocellular carcinoma. Partner Jazz will highlight Ziihera® in HER2-driven gastrointestinal cancers. Zymeworks' management will also present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:00 pm PT. Zymeworks focuses ...
12-02 21:05
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从6美元升至8美元;HC Wainwright & Co.:维持MediWound"买入"评级,目标价从31美元升至36美元
11-24 11:23
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. announced that its management will participate in two upcoming investor conferences: the Evercore 8th Annual Healthcare Conference on December 2, 2025, and the Citi 2025 Global Healthcare Conference on December 3, 2025, both in Miami, FL. Zymeworks is a global biotechnology company developing innovative biotherapeutics for treating difficult-to-treat diseases such as ca...
11-24 11:00